What she is here for: the only figure in the Moonshots with Peter Diamandis corpus who built four satellite companies and then left space entirely — and the guest of Moonshots #290, where she is the sole source for every claim about her own Nasdaq-listed company.
Why she is in this archive
Gate: cited in 2 episodes — named as a BETA Technologies investor on moonshots 279
1:58:27, and the sole guest of Moonshots #290. Promoted 2026-09-24 off the EP290
decomposition. She sits at the intersection of three Gonçalo lanes at once: space, longevity, and
AI-for-engineering.
The career, in the order it happened
Verified against primary sources on 2026-09-18 — full working in the research archive §2.
| period | what | status |
|---|---|---|
| 1977–81 | UCLA: thesis on direct-broadcast satellites; MBA business plan for Hughes that became the PanAmSat plan | VERIFIED |
| 1984 | Retained by Rene Anselmo to implement it — PanAmSat, the first private international satellite system | VERIFIED |
| 1986– | CEO of Geostar Corp. — satellite geolocation. She was retained by Gerard K. O'Neill himself for business and regulatory matters | VERIFIED |
| 1990 | Creates WorldSpace (first global satellite radio network) and Sirius Satellite Radio — first chairman & CEO of Sirius; led the FCC effort that created the satellite-radio service | VERIFIED |
| 1996 | Founds United Therapeutics (Nasdaq: UTHR) to save her daughter from pulmonary arterial hypertension | VERIFIED |
| Sep 2026 | UTHR market cap $21.3–21.6B in the week EP290 aired (a market number: it moves daily) — Peter says "28 billion" on tape (0:03:29) |
CONTRADICTED on the number |
She left space for biology in 1996 and has not gone back. On tape she says why, without being
asked: "over the from the 80s when we we spent all our time with space settlements till now, I have
become a total biotechnologist." (Moonshots #290 0:39:14)
Her operating frame — the three checks
Stated twice, and it is the most transferable thing in the episode:
"I have to feel that I'm able to successfully achieve it. And if I can successfully achieve it and um be the best at it and it be something that's going to have a positive impact, a big positive impact on the world, then I go for it."
0:05:04
- Competency — "make sure that you're focusing on something that you have the competency to
succeed at"
0:09:08 - Best, not me-too — "There's always room at the top… not like a meto person at the bottom
because you'll be ground out into business failure"
0:09:29 - Scales to billions — "is that a technology that can be scaled to billions of people… If
it's a technology that cannot be scaled to more than a few thousand people, probably have a
great restaurant."
0:10:13
Supporting moves: "multiple shots on goal" (0:17:51, four parallel thymus programs);
"95% now is vastly better than 100% in some misty future" (0:35:17); the criticism discipline —
"I look at each no as a way to make me smarter… I evaluate whether it has merit" (0:07:12),
with a pilot's traffic-scan analogy; and a five-year commercialisation horizon
(0:47:45) because "it's difficult to get people to work for more than like a 5-year time frame."
Read her own career against her own test: in 1996 space failed check 3 and biology passed it. Nobody on tape asks her that. See Moonshots #290 anatomy §8.
The engineering constraint worth stealing
"when we manufacture an organ, it's got a 12-hour halflife. It's not like a bottle of pills that can stay in your counter for a year. We have to once we make it, we have to give it to the person within 12 hours."
0:43:36
That is why she funds electric aircraft. A 12-hour perishability constraint generated an entire
aviation investment thesis — moonshots 279 1:58:27 names her and Dean Kamen as "big
investors" in BETA Technologies (336 nmi range, cargo first with UPS). UT is also a BETA
strategic partner and first customer, and BETA flew UT-manufactured organs on the first FAA
electric-aircraft operational flights, 2026-07-10. The episode delivers this as an aside.
Positions and ties disclosed on tape
| tie | verbatim | where |
|---|---|---|
| Founder & CEO, United Therapeutics — the subject of every organ claim in EP290 | — | throughout |
| Ray Kurzweil on her board — disclosed while invoking him as the LEV authority. She says "30 years"; UT proxies say since 2002 (~24) | "Ray has been a member of our board of directors for 30 years." | 0:11:40 |
| George Church was first shareholder of Thymmune, which UT then acquired — disclosed while citing him as the independent expert who validated her | "He was the first shareholder in Thymune." | 0:06:31 |
| Multi-million-dollar donor to Alcor | "I've made, you know, multi-million dollar donations to Alor." | 0:36:00 |
| Funds the National Space Society settlement prize she cites on air | "I've been funding this prize at the National Space Society to uh to live on an O'Neal settlement in our lifetime" | 0:36:33 |
| Investor in BETA Technologies (with Dean Kamen) — named by Dave, not by her | "Dean Kamen, uh Martine Rothblatt are big investors in this one" | moonshots 279 1:58:27 |
⚠️ No "full disclosure" and no financial disclaimer is said in the entire episode. → Moonshots: the disclosures ledger.
What she believes, verbatim
- AI consciousness is already here: "I believe we're there now and I believe the current models
will take us there… consciousness is not like a digital eitheror thing. It's a continuum."
0:30:13 - Legal personhood follows a court case: "it'll happen also not later than the 2030s for sure
100%."
0:32:44⚠️ The episode title says "by 2030." The tape says "the 2030s." Quote the tape. - Uploading beats the connectome: you don't need every neuron — an LLM trained on
"all of our videos, our audios, our documents, our conversations" yields a digital
approximation "indistinguishable from us."
0:34:33. Evidence offered: hemispherectomy patients. - On fear: "fears are like cockroaches. Um they dominate in darkness and ignorance and as soon
as you flip on the … light the cockroaches vanish."
0:45:28 - Self-positioning: "Elon's role is to spread consciousness to the cosmos and my role is to
provide endless endless life for that consciousness."
0:44:55 - On O'Neill: "first and foremost, I admired him as a maker. Makers are my people. That's my
favorite tribe."
0:40:59— praising him for running the numbers and publishing them in Physics Today, and for the courage to say it as an APS member. - She declines the moon-vs-Mars call: "It really is beyond my competence."
0:39:14
On tape vs reality
Three reads, not one. Close means the number is near enough to repeat with the correction. Off means don't repeat it. Aspiration means a forward claim about what the company is trying to build: not a fact yet, and the thing worth following over time.
| on tape | reality | read |
|---|---|---|
Kurzweil a director "for 30 years" 0:11:40 |
proxies: director since 2002 (~24 years) | Close. Say "about 24 years" |
"unlimited supply" of kidneys 0:23:16, hearts 0:24:51, xeno-thymi 0:20:34 |
UT's own 10-K: up to 125 organs/yr per facility, three facilities | Aspiration: investigate. Where they are aiming, not what they make today. Track the facility count and output |
xeno-organ survival "should be indefinite" 0:25:11 |
forward claim, no data yet | Aspiration: investigate |
"after 50 patients in the xeno heart clinical trial we should have FDA approval" 0:24:51 |
UHeart/EXPRESS IND cleared 2026-05-15 with an initial cohort of up to 2 | Aspiration: investigate. Her projection, not the release |
IVIVA autologous kidney trials "in 2028" 0:23:58 |
IVIVA is preclinical; the 2028 date is unverified | Aspiration: investigate |
Marvatar available to "all 2,000 United Therapeutics employees" 0:29:41 |
10-K: ~1,400 employees at 31 Dec 2025 | Off. Use ~1,400 |
"We kept both of these individuals alive for over 60 days" (xeno-heart) 0:24:20 |
Bennett 60 days (2022); Faucette ~40 days (2023) | Off. Not both |
| the waitlist, heart-disease and T-cell numbers | see Longevity escape velocity (LEV) ⚠️ table | see there |
What to take from her
The three checks are a real screen and they survive translation out of biotech. The 12-hour half-life → aircraft chain is the cleanest example in the corpus of a physical constraint generating an adjacent business — the pattern Gonçalo cares about. And her career is the corpus's one worked example of an operator who applied her own scale test to space, got a "no" in 1996, and moved. That is worth taking seriously rather than dismissing, and it is the question the episode never asks.
To investigate: how she actually operates
The episode gives the screen, not the machinery behind it. The open questions worth a deep dive, or an interview:
- The competency model. She says "focus on something that you have the competency to succeed at". How does she test that she has the competency before she commits, and how did that test change between satellites and biotech?
- Energy. Four satellite companies, then a public biotech, then organ manufacturing. What keeps that sustained over forty years?
- People. How she finds and keeps the people who can build what she can't: the O'Neill, Anselmo, Kurzweil and Church relationships are the visible part.
- Organising herself. How she runs parallel bets ("multiple shots on goal") without spreading too thin.
- Cash flow. How each company was financed through the years before revenue: PanAmSat, Sirius, and United Therapeutics before its first approved drug.
Where it came up
- Moonshots #290 — the full guest interview, 2026-09-15 (recorded 2026-07-30)
- moonshots 279
1:58:27— named as a BETA Technologies investor, in a flying-cars segment
⚠️ Unverified
All quotes are from auto-captioned transcripts; caption mangles (Martin Rothblad, thymune,
allergenic, Alor) are preserved in the anatomy. Company facts are checked against UT press
releases, the 2025 10-K and proxy statements as of 2026-09-18; nothing here is re-checked against
filings published since.